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César Milstein: October 8, 1927–
March 24, 2002
César Milstein died in the early hours of 24th March 2002. He
had a long history of cardiovascular illness, to which he finally
succumbed. We will always remember his enthusiasm for sci-
ence and his kind attention to the problems of others. His most
famous contribution to biology was the invention of monoclonal
antibodies (also called hybridomas, but that was a term he
never really liked) for which he was awarded the Nobel Prize for
Physiology or Medicine in 1984, along with George Kohler, who
worked with César on the key experiments that led to their land-
mark paper, published in Nature in 1975.
César was born in Argentina in 1927 and developed an
early interest in immunology through family connections; this
was an enthusiasm that was to last throughout his sparkling
career. After being a none-too-keen schoolboy, he went to
Buenos Aires University to study chemistry. He obtained a BSc
and then a Ph.D. studying aldehyde dehydrogenase in the lab-
oratory of Andres Stoppani. He later traveled to Cambridge,
England, and worked in the University Department of Bio-
chemistry with Malcolm Dixon, where he obtained a second
Ph.D. with studies on the phosphoglucomutase enzyme. It was
in the Department of Biochemistry that César met Fred
Sanger, who was to be influential in attracting him back to
Cambridge after a brief sojourn in his old Buenos Aires
Institute as Head of Molecular Biology. César’s move to the
then-fledgling Laboratory of Molecular Biology with Fred, and a
truly extraordinary group of scientists (Brenner, Crick, Huxley,
Kendrew, Klug, Perutz), was a wonderful opportunity for him as
the MRC support allowed his research to blossom by setting
few constraints on what he could do. How well-suited this envi-
ronment must have been for the young Milstein! The intellectual
environment was second to none, and it was there that he
developed an interest in antibody structure and diversity, unfet-
tered by the needs of the next grant proposal or the next peer
review committee.
An interest in antibody diversity was to stretch from those
early times until César’s death (he had submitted a paper to
PNAS just the week before he died). When he joined the
Laboratory of Molecular Biology, he started thinking about
potential roles of germline immunoglobulin gene diversity or of
somatic diversification of those genes, and he came to the con-
clusion that the latter mechanism must lie at the heart of anti-
body diversity. This one fundamental belief was the precursor
for the work that was eventually to lead to his Nobel Prize-win-
ning work with Kohler. In his attempts to solve the issue of
somatic diversification, Milstein collaborated with George
Brownlee on pioneering sequencing work of immunoglobulin
light-chain mRNA. This involved labeling mouse myeloma cells
with >50 mCi 32P, followed by preparation of purified mRNA for
fingerprinting. The days of the “hot preps” were usually
Thursdays and would involve César and John Jarvis, his
research associate, garbed in full-length lead aprons, spinning
5 liters or more of radioactive myeloma cells to concentrate
them into a few milliliters. This would invariably result in a trail of
radioactivity across the corridor from the cold room to the hot
room where these procedures were carried out. These studies,
plus immunoglobulin protein synthesis work, showed that the
precursor of the light chain was made with a hydrophobic leader
sequence for specifying transfer to the endoplasmic reticulum.
César always tackled scientific problems from many angles,
and he was not content with straight molecular biology. Rather,
he was also keen to see if cells could discriminate immunoglob-
ulin heavy and light chains of differing origins, and he set about
fusing rat and mouse immunoglobulin-producing cell lines. With
Dick Cotton, many experiments were done to show how heavy
and light chains associate. Later, George Kohler joined César’s
group as a post-doc. Together they hatched the idea of fusing
spleen cells with mouse myeloma tissue culture cells to immor-
talize the spleen immunoglobulin and, of course, the stroke of
brilliance here was that preimmunizing mice with antigen
allowed predefined antibody specificities to be captured. This
became monoclonal antibody technology. Their paper was pub-
lished in 1975, and the Nobel Prize was awarded in 1984. César
was awarded innumerable additional prizes for this work. He
received other accolades such as the Companion of Honor in
1995, and he became the first recipient of the MRC Millennium
Medal in 2000. He was a Fellow of the Royal Society of London
and of the National Academy of Sciences.
Monoclonal antibody technology was revolutionary
because, for the first time, pure antibody species of defined
specificity could be made. This had far-reaching implications for
biological research and for clinical use (diagnostics and, more
recently, therapeutics). Early in the development of monoclonal
antibodies, César started to work on monoclonals recognizing
surface antigen markers and blood groups. Monoclonal antibod-
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ies are now the basis of many diagnostic assays for proteins in
clinical laboratories and have important uses in such areas as
cancer imaging. Now their value as therapeutic agents is at last
beginning to emerge. For instance, we have recently heard
about Herceptin, a monoclonal antibody that binds to a surface
receptor and is proving important in management of breast can-
cers. Therapeutic use of monoclonal antibodies had been
César’s dream, and he had the gratification of seeing the
process put into practice. Discussions about whether monoclon-
al antibodies should have been patented in 1975 have occupied
many people. However, we should remember the immense
importance of the invention, which was nurtured from essential-
ly curiosity-driven research. As with almost all inventions,
hybridoma technology seems blindingly obvious many years
later, but the fact remains that monoclonal antibodies are just
beginning to be widely accepted for treatment regimes (and at
this time, of course, an original monoclonal antibody patent
would be off-patent!).
After hybridomas, César remained true to his early scientif-
ic obsession (namely, how somatic mutation arises in
immunoglobulin genes) despite his success with monoclonal
antibodies and the acclaim this brought him. He mapped out
patterns of changes observed during antibody responses using
primer-directed cDNA sequencing. This work charted the
course of somatic diversification in an immune response. Even
when César formally retired in 1995, he remained an active
member of the Protein and Nucleic Acid Chemistry Division in
the Laboratory of Molecular Biology. In his postretirement years,
he continued his interest in the origin of somatic mutation and,
in collaboration with Michael Neuberger, he had begun to dis-
sect the enzymatics of the process. Indeed, César’s only con-
cession to retirement was not to work on Saturdays any more.
César was a prolific writer and published 313 papers in his life-
time, each composed with his characteristic precision.
The way that César confronted the symptoms of his cardio-
vascular illness was typical of him. His illness was first diag-
nosed some 20 years ago, and he set about finding all the data
he could about it, examining it and deciding how he was going
to fight it. He switched from a high-cholesterol diet to low-cho-
lesterol salads and the like, and he immediately took to long
walks around Cambridge, before and after work, to stimulate his
circulation. He identified a series of local and London restau-
rants that were able to cope with his strict dietary regime, and of
course high tables in the Cambridge colleges were not spared.
Occasionally, César gave in to impulse, such as his nearly dis-
astrous white-water rafting in Chile, during which he had a “life-
threatening cardiovascular episode,” as he casually put it when
he returned to work. However, he was generally tenacious in his
health regime; one often reads of people fighting their disease,
but César truly did.
César’s qualities as a researcher go without saying, but I
am sure he would not mind my saying that he was not a well-
organized scientist. He would not come to the lab with a list of
“things to do today.” Rather, his style was intellectual, grasping
at problems as they arose in the laboratory simply for their sake
as scientific problems. He always seemed to have masses of
time to discuss and mull over data. His suggestions were not
always the most down-to-earth, but therein lay his brilliance; at
one time completely outlandish and at another focused and hit-
ting the spot. Those of us who had the privilege to work at the
Laboratory of Molecular Biology with César over the years will
remember him as a father figure and a friend. He used to
describe the Laboratory of Molecular Biology as the “beloved
Laboratory,” and that was his inspiration. There was another
side to César, and it was the one who loved his wife Celia,
whom he married in 1953, who loved his home, his garden, his
boat, and manifold other special things in life like music, art, cin-
ema, and theater. Of all the things we shall remember about
César, his enthusiasm for science was special. At César’s
funeral, Michael Neuberger told us that César had mentioned in
a recent press interview that he wished to be remembered as a
nice chap. As Michael said, César’s wish has been granted
many times over, “he was a very nice chap.”
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